In the first series of MuSK-MG, in addition to a more severe clinical picture with respiratory crises, female predominance and early onset, the lack of response to anticholinesterase drugs and the need for additional aggressive immunosuppression was the most common scenario. This concept was dramatically modified with the use of Rituximab. We present our experience in the treatment of 27 patients with Myasthenia Gravis anti-MuSK. We evaluated the treatments received, and the therapeutic response according to clinical and post-interventional status (PIS) of the Myasthenia Gravis Foundation of America (MGFA) at 6, 12, 24 months and current in a cohort of Musk-MG patient.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...